Innovative treatment for prostate cancer shows long-term success

In this case report, PHM summarizes the treatment course for a 73-year-old male patient, who came to PHM for assistance in managing his metastatic castration-resistant prostate cancer. In 2016, after almost two years of standard treatments, including hormone therapy and chemotherapy, there were signs that his cancer was worsening. PHM was able to connect him with a treatment facility in Germany that was employing an emerging pair of technologies that could potentially help, but were not yet approved in the U.S.